Cargando…
Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
INTRODUCTION: Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established. CASE PRESENTATION: We described a case of castration‐resistant prostate cancer with neuroendocrine differentiation after initial external be...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249630/ https://www.ncbi.nlm.nih.gov/pubmed/35795118 http://dx.doi.org/10.1002/iju5.12442 |
_version_ | 1784739626395631616 |
---|---|
author | Komori, Takahiro Kosaka, Takeo Watanabe, Keitaro Tanaka, Tomoki Yasumizu, Yota Hongo, Hiroshi Mikami, Shuji Ohashi, Toshio Oya, Mototsugu |
author_facet | Komori, Takahiro Kosaka, Takeo Watanabe, Keitaro Tanaka, Tomoki Yasumizu, Yota Hongo, Hiroshi Mikami, Shuji Ohashi, Toshio Oya, Mototsugu |
author_sort | Komori, Takahiro |
collection | PubMed |
description | INTRODUCTION: Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established. CASE PRESENTATION: We described a case of castration‐resistant prostate cancer with neuroendocrine differentiation after initial external beam radiotherapy followed by salvage androgen deprivation therapy. Magnetic resonance imaging detected recurrence of a suspicious lesion in the left lobe of the prostate, although the prostate‐specific antigen level was <0.2 ng/mL. Transperineal prostate saturation needle biopsy detected adenocarcinoma with neuroendocrine differentiation. The patient underwent salvage focal brachytherapy and had a prostate‐specific antigen progression‐free survival of 20 months with no obvious adverse events. No recurrence has been detected on magnetic resonance imaging for 18 months. CONCLUSION: Salvage focal brachytherapy for prostate cancer after external beam radiotherapy can be one of the treatment strategies for local recurrence of castration‐resistant prostate cancer with neuroendocrine differentiation. |
format | Online Article Text |
id | pubmed-9249630 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92496302022-07-05 Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy Komori, Takahiro Kosaka, Takeo Watanabe, Keitaro Tanaka, Tomoki Yasumizu, Yota Hongo, Hiroshi Mikami, Shuji Ohashi, Toshio Oya, Mototsugu IJU Case Rep Case Reports INTRODUCTION: Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established. CASE PRESENTATION: We described a case of castration‐resistant prostate cancer with neuroendocrine differentiation after initial external beam radiotherapy followed by salvage androgen deprivation therapy. Magnetic resonance imaging detected recurrence of a suspicious lesion in the left lobe of the prostate, although the prostate‐specific antigen level was <0.2 ng/mL. Transperineal prostate saturation needle biopsy detected adenocarcinoma with neuroendocrine differentiation. The patient underwent salvage focal brachytherapy and had a prostate‐specific antigen progression‐free survival of 20 months with no obvious adverse events. No recurrence has been detected on magnetic resonance imaging for 18 months. CONCLUSION: Salvage focal brachytherapy for prostate cancer after external beam radiotherapy can be one of the treatment strategies for local recurrence of castration‐resistant prostate cancer with neuroendocrine differentiation. John Wiley and Sons Inc. 2022-04-28 /pmc/articles/PMC9249630/ /pubmed/35795118 http://dx.doi.org/10.1002/iju5.12442 Text en © 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Case Reports Komori, Takahiro Kosaka, Takeo Watanabe, Keitaro Tanaka, Tomoki Yasumizu, Yota Hongo, Hiroshi Mikami, Shuji Ohashi, Toshio Oya, Mototsugu Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy |
title | Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy |
title_full | Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy |
title_fullStr | Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy |
title_full_unstemmed | Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy |
title_short | Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy |
title_sort | salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249630/ https://www.ncbi.nlm.nih.gov/pubmed/35795118 http://dx.doi.org/10.1002/iju5.12442 |
work_keys_str_mv | AT komoritakahiro salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy AT kosakatakeo salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy AT watanabekeitaro salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy AT tanakatomoki salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy AT yasumizuyota salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy AT hongohiroshi salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy AT mikamishuji salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy AT ohashitoshio salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy AT oyamototsugu salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy |